From my understanding--I don't have access to the J of U (but almost all the articles are free in the month of Feb), haven't seen the whole article but I would think that means the other 71% of pts did not have more tumors found by using additional blue light to the white light cystoscopy.
"A comparative study between GE Healthcare's Hexvix® fluorescence cystoscopy and white light cystoscopy has shown that Hexvix® cystoscopy is more effective in the detection of Ta and T1 papillary lesions than white light1 cystoscopy alone in 29% patients. The study has been published in this month's Journal of Urology issue."
We've already seen that it's usefulness in detecting CIS is confirmed (
), now this phase III trial reported by American experts is claiming it's effectiveness at diagnosing more papillary tumors.
I would think there is enough data now to get this tool approved for use in the US.